The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization be granted for a new diagnostic radiopharmaceutical, flutemetamol (18F) (Vizamyl, 400 MBq/mL, GE Healthcare Ltd), for the visual detection of amyloid-β neuritic plaques in the brain of patients with cognitive impairment suspected of having Alzheimer's disease, in conjunction with clinical evaluation.
Fonts: Medscape
Nessun commento:
Posta un commento